(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 September 2011 (15.09.2011)

PCT

(10) International Publication Number
WO 2011/110859 A1

(51) International Patent Classification:
C07D 487/04 (2006.01) *A61P 1/00* (2006.01)
A61K 31/519 (2006.01) *A61P 11/00* (2006.01)

(21) International Application Number:
PCT/GB2011/050478

(22) International Filing Date:
10 March 2011 (10.03.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1004179.6 12 March 2010 (12.03.2010) GB

(71) Applicant *(for all designated States except US)*: **PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED** [GB/GB]; Fulmer Hall, Windmill Road, Fulmer, Slough Berkshire SL3 6HD (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **EDWARDS, Christine** [GB/GB]; c/o Pulmagen Therapeutics (Inflammation) Limited, Fulmer Hall, Windmill Road, Fulmer, Slough Berkshire SL3 6HD (GB). **KULAGOWSKI, Janusz** [GB/GB]; c/o Pulmagen Therapeutics (Inflammation) Limited, Fulmer Hall, Windmill Road, Fulmer, Slough Berkshire SL3 6HD (GB). **FINCH, Harry** [GB/GB]; c/o Pulmagen Therapeutics (Inflammation) Limited, Fulmer Hall, Windmill Road, Fulmer, Slough Berkshire SL3 6HD (GB).

(74) Agent: **PERRY, Robert, Edward**; Gill Jennings & Every LLP, The Broadgate Tower, 20 Primrose Street, London, Greater London EC2A 2ES (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2011/110859 A1

(54) Title: PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF RESPIRATORY DISEASES SUCH AS COPD



(I)

(57) Abstract: Compounds of formula (I) are inhibitors of neutrophil elastase, wherein A is C-R^1 or N; -X^1-X^2- is CR^{15}=N- or -NR^{19}-CO-; and R^1-R^6, R^{15} and $R^{16}$are as defined in the claims.